Amarin Corporation’s cardiovascular study is nearing completion

Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.

This marks an important step in completion of this potentially landmark study, as the patients return to their clinical sites for final study data collection. The final patient visits begins on March 1, 2018 is consistent with the company’s estimated schedule of having results of this first of its kind study announced before the end of the third quarter of this year, Amarin said in its press release.

As Dr. Steven Ketchum, Amarin senior vice president, president of R&D, and chief scientific officer, the start of final patient visits is a positive step towards completing this six-year, 8,175 patient study.

“We are excited that the REDUCE-IT trial is nearing completion and appreciative for the participation of patients and clinical sites in this important clinical study,” KDR*. etchum said.

Image: Amarin Corporation Chief Scientific Officer Steven Ketchum